MECHANISMS OF RESISTANCE TO MENIN INHIBITOR THERAPY AND ACUTE MYELOID LEUKAEMIA
With
Dr Rithin Nedumannil,
Consultant Haematologist and PhD Candidate,
Peter MacCallum Cancer Centre,
Austin Health,
Eastern Health,
Royal Melbourne Hospital
Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | June 2025
Dr Rithin Nedumannil (MBBS, MPH, FRACP, FRCPA) is a PhD candidate at the University of Melbourne, undertaking his doctoral studies in collaboration with the Cambridge Stem Cell Institute (Cambridge, UK) and the Peter MacCallum Cancer Centre (Melbourne, Australia). He is a clinical haematologist and haematopathologist with current appointments at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, Austin Health and Northern Health.
After completing his medical degree at the University of Adelaide, Dr Nedumannil undertook advanced training in clinical and laboratory haematology across Melbourne’s major tertiary centres. He was awarded dual fellowships (FRACP and FRCPA) and went on to complete a subspecialty fellowship in Acute Leukaemia and Myelodysplastic Syndromes at Peter MacCallum Cancer Centre and the Royal Melbourne Hospital in 2024. He also holds a Master of Public Health from the University of New South Wales.
His interest in translational leukaemia research has been shaped by extensive clinical experience and academic work focusing on measurable residual disease, novel fusion genes and treatment resistance in acute leukaemias. His PhD will explore resistance mechanisms to menin inhibitors in acute myeloid leukaemia (AML) using genome-scale technologies including CRISPR screening, RNA sequencing and epigenomic profiling. His research will be conducted over two years at the Cambridge Stem Cell Institute and one year at Peter MacCallum Cancer Centre.
For this work, Dr Nedumannil has been awarded the 2025 Haematology Society of Australia and New Zealand and Leukaemia Foundation New Investigator PhD Scholarship, supporting his goal of translating molecular insights into improved therapeutic strategies for high-risk AML.
Source: Supplied
https://orcid.org/0000-0002-0883-3942
-
Investigating new approaches to target plaque inflammation in atherosclerosis
Associate Professor Peter Psaltis is an Academic Interventional Cardiologist who holds Level 2 NHMRC Career Development and National Heart Foundation Future Leader Fellowships. He has Faculty positions within the University of Adelaide, Central Adelaide Local Health Network (CALHN) and South Australian Health and Medical Research Institute (SAHMRI). Within SAHMRI, he is the Co-Theme Leader of the Lifelong Health, Program Leader of Heart and Vascular Health and Co-director of the Vascular Research Centre in the Lifelong Health Theme.
-
Vision impairment in children and the impact on children and their families
Dr Sue Silveira holds a conjoint academic position with Macquarie University and is the Course Director for their Master of Disability Studies, which is administered and delivered by NextSense Institute in affiliation with the University. She teaches in the areas of vision impairment and disability, and aims to share her knowledge while learning from others, especially people who are blind or have low vision and their families.
-
Prescribing exercise to regional population with cardiovascular disease & diabetes
Associate Professor Gordon’s research is aimed at determining the optimal methods of prescribing and implementing exercise as part of the health care plan for people with cardiovascular disease and diabetes. Specifically, he is leading work to determine if and how the components of exercise can be considered as a whole for prescribing exercise to generate health benefits. This is important to overcome the series of barriers that people living in rural and regional areas experience when trying to become active.
